Minerva (NERV) - Earnings per share growth in current year
A critical risk for Minerva Neurosciences (NERV) remains a potential FDA rejection and a lack of funds. However, the development of roluperidone opens a unique niche by helping to overcome social isolation in schizophrenia. The drug's success will provide the company with pricing power due to inelastic demand. On GURU.Markets, the final annual EPS growth figure demonstrates profit dynamics, where -5.10 describes the current status of the metric.
Financial and market metric breakdowns for Minerva Neurosciences (NERV)
- stock price and consensus target price:
- market capitalization indicators:
- book capitalization indicators:
- debt burden and liquidity indicators:
Debt to Equity Ratio Minerva Neurosciences|NERV - Long-Term Debt to Capital|Current Liabilities to Capital minervaneurosciences.com|NERV - Company Total Debt|Debts to Book Capitalization Minerva|NERV - Company Long-Term Debt|Company Short-Term Loans and Borrowings Minerva Neurosciences|Immediate Liquidity minervaneurosciences.com
- earnings and market multiples details:
NERV - Company Net Income|Company Profit Forecast Minerva Neurosciences|NERV - P/E Multiple|Projected Price to Earnings Minerva|NERV - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Minerva|NERV - Operating profit EBITDA|Net earnings per one share for the last twelve months Minerva Neurosciences|NERV - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months minervaneurosciences.com|NERV - Earnings growth in current year|Expected earnings per share growth for next year Minerva Neurosciences
Summary company analysis:Minerva Neurosciences
The financial performance of Minerva Neurosciences (NERV) depends directly on the success of clinical trials for CNS drugs. This indicator captures the percentage change in earnings per share compared to the previous year. By analyzing annual EPS growth, investors assess the monetization efficiency of the company's diversified small-molecule portfolio. The intraday timeframe eliminates reporting lags, revealing the real resilience of the business. A steady uptrend confirms the company's maturity and the minimization of regulatory risks.
Main competitors
Biogen Inc - Earnings per share increase in current year|Net earnings per share growth this year NBIX|Earnings per share growth in current year RGC|Earnings growth in current year AXSM|Earnings growth in current year acadia-pharm.com (ACAD)|Xenon - Net earnings per share growth this year|Earnings per share increase in current year VKTX|SUPN - Earnings per share growth in current year|CPRX (Catalyst Corp) - Earnings per share growth this year|DNLI: Earnings growth in current year|Earnings per share growth rate in current year harmonybiosciences.com (HRMY)|Net earnings per share growth this year BHVN|Earnings growth in current year Amylyx Pharmaceuticals Inc|Earnings per share growth in current year Trevi Pharma (TRVI)|PRAX (Praxis Corp) - Earnings per share increase in current year|Earnings per share growth in current year Anavex Life Sciences AVXL|ceribell.com (CBLL) - Earnings per share growth rate in current year|PRTA - Earnings per share growth in current year|Expected net earnings per share growth this year Alector, Inc. ALEC|ANNX: Earnings growth in current year|Net earnings per share growth this year Omeros|NGNE (Neurogene Inc.) - Earnings growth in current year|acimmune.com (ACIU) - Expected net earnings per share growth this year|Earnings growth in current year VYGR|NMRA - Earnings per share growth rate in current year|Earnings per share growth in current year Scilex Holding Co. SCLX|TVGN: Earnings per share growth this year|Alpha Cognition Corp - Earnings growth in current year|Cognition Therapeutics Inc. (CGTX) - Net earnings per share growth this year|IKT: Earnings growth in current year|Earnings per share growth rate in current year Cassava Sciences Inc (SAVA)|Earnings per share growth in current year Assertio Holdings|Coya (COYA) - Expected net earnings per share growth this year|Earnings per share growth in current year Vistagen Therapeutics (VTGN)|ovidrx.com - Earnings per share growth this year|Earnings growth in current year ABOS (Acumen Pharmaceuticals, Inc.)|CervoMed, Inc. (CRVO) - Earnings per share growth rate in current year|ATHE - Earnings per share growth in current year|Earnings per share increase in current year CLNN (Clene Inc.)|PEPG (pepgen.com) - Net earnings per share growth this year|JUNS (Jupiter Neurosciences, Inc.) - Earnings per share growth in current year|Earnings per share growth in current year Relmada Therapeutics, Inc.|Earnings per share growth this year ANVS (Annovis Bio Inc)|Earnings growth in current year GRCE|AIFF - Earnings per share growth rate in current year|Klotho Neurosciences - Net earnings per share growth this year|Earnings growth in current year NeuroSense Therapeutics Ltd NRSN|RVPH - Earnings per share growth in current year|Earnings per share increase in current year MTVA (MetaVia Inc)|NeurAxis, Inc (NRXS) - Earnings per share growth in current year|Earnings per share growth rate in current year Helius Medical Technologies (HSDT)|Earnings per share growth in current year Passage Bio Inc.|Net earnings per share growth this year Neuphoria (NEUP)|Earnings growth in current year ATHA|Expected net earnings per share growth this year Addex Therapeutics Ltd.|Earnings per share growth in current year Alzamend Neuro ALZN|CYCN: Earnings per share growth this year|Protagenic - Earnings growth in current year|Earnings per share growth rate in current year Pasithea Therapeutics|cortigent.com (CRGT) - Earnings per share growth in current year|Avenue Therapeutics Inc. - Earnings per share increase in current year|Net earnings per share growth this year BCLI|Earnings per share growth in current year CARA|Earnings growth in current year CHRO|Earnings growth in current year eliemtx.com (ELYM)|Intra-Cellular Therapies, Inc. - Net earnings per share growth this year|Earnings per share increase in current year LBPH|MRNS - Earnings per share growth in current year|NKGN (NKGen Biotech Corp) - Earnings per share growth this year|NRBO: Earnings growth in current year|Earnings per share growth rate in current year sagerx.com (SAGE)|Net earnings per share growth this year SNPX|Earnings growth in current year Trevena Inc.|Earnings per share growth in current year Vigil Neuroscience (VIGL)|WENA (anewmeds.com) - Earnings per share increase in current year|Earnings per share growth in current year Cerevel Therapeutics CERE
